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Abstract
Purpose Quantitative accuracy of positron emission tomogra-
phy (PET) is affected by partial volume effects resulting in
increased underestimation of the standardized uptake value
(SUV) with decreasing tumour volume. The purpose of the
present study was to assess accuracy and precision of different
partial volume correction (PVC) methods.
Methods Three methods for PVC were evaluated: (1)
inclusion of the point spread function (PSF) within the
reconstruction, (2) iterative deconvolution of PET images
and (3) calculation of spill-in and spill-out factors based on
tumour masks. Simulations were based on a mathematical
phantom with tumours of different sizes and shapes.
Phantom experiments were performed in 2-D mode using
the National Electrical Manufacturers Association (NEMA)
NU2 image quality phantom containing six differently sized
spheres. Clinical studies (2-D mode) included a test-retest
study consisting of 10 patients with stage IIIB and IV non-
small cell lung cancer and a response monitoring study
consisting of 15 female breast cancer patients. In all studies
tumour or sphere volumes of interest (VOI) were generated
using VOI based on adaptive relative thresholds.
Results Simulations and experiments provided similar
results. All methods were able to accurately recover true
SUV within 10% for spheres equal to and larger than 1 ml.
Reconstruction-based recovery, however, provided up to
twofold better precision than image-based methods. Clinical
studies showed that PVC increased SUV by 5–80% depending
on tumour size. Test-retest variability slightly worsened from
9.8±6.5 without to 10.8±7.9% with PVC. Finally, PVC
resulted in slightly smaller SUV responses, i.e. from −30.5%
without to −26.3% with PVC after the first cycle of treatment
(p<0.01).
Conclusion PVC improves accuracy of SUV without
decreasing (clinical) test-retest variability significantly and
it has a small, but significant effect on observed tumour
responses. Reconstruction-based PVC outperforms image-
based methods, but requires dedicated reconstruction
software. Image-based methods are good alternatives because
of their ease of implementation and their similar performance
in clinical studies.
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Introduction
In oncology, positron emission tomography (PET) using 18F-
2-fluorodeoxy-D-glucose (FDG) is increasingly being used
for differentiation between benign and malignant tumours,
for tumour staging, for diagnosis of post-treatment recur-
rence, for determination of response to therapy and for
prognostic purposes. Most of these applications take advan-
tage of the capability of PET to quantify tissue radioactivity
concentration [1].
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Amongst various approaches to assess FDG uptake, the
standardized uptake value (SUV) is widely used as a semi-
quantitative index of tumour uptake [2]. SUV represents
radioactivity concentration at a certain time, normalized for
body distribution (i.e. body weight, body surface area or
lean body mass) and injected dose. Apart from the fact that
SUV is time dependent, i.e. changing with time after FDG
injection [3], it also is affected by more technical factors,
such as method of data acquisition, image reconstruction
algorithm and applied region of interest (ROI) strategy [4].
In addition, the so-called partial volume effect results in
increasing underestimation of SUV with decreasing tumour
volume [5].
The partial volume effect is due to the limited spatial
resolution of PET scanners (typically 5–7 mm full-width at
half-maximum, FWHM) and it can be expressed by a
recovery coefficient, i.e. the ratio between measured and
true activity concentrations [6, 7]. The low spatial resolu-
tion results in partial spread of signal from a tissue of
interest into neighbouring tissues (‘spill-out’), but also from
those neighbouring tissues into the target tissue (‘spill-in’).
For tumours smaller than the reconstructed spatial resolu-
tion, the partial volume effect may result in a more than
50% underestimation of the true FDG concentration [6].
Various partial volume correction (PVC) methods have
been developed to overcome or correct for the limited
resolution of a clinical PET scanner [6, 8–10]. Some of
these methods, specifically designed for human brain
studies, use high-resolution anatomical images to correct
for partial volume effects [9, 11, 12]. These methods
generally use a coregistered structural magnetic resonance
imaging (MRI) scan that is segmented into grey matter
(GM), white matter (WM) and cerebrospinal fluid (CSF)
regions. These segmented MRI scans can be used to correct
reconstructed PET images for partial volume effects either
at a parametric [13, 14] or a ROI level [15, 16]. A
disadvantage of the use of these high-resolution anatomical
images is the need for accurate registration with the PET
images [17]. Inaccurate segmentation or misregistration can
result in PVC errors. Nevertheless, when these techniques
are applied to brain studies, they work reasonably well
[15, 16]. For whole-body studies computed tomography
(CT) can also be used for anatomical imaging. In cases of
oncological applications, however, there are several limi-
tations: (a) metabolic PET and anatomical CT/MRI tumour
boundaries do not necessarily coincide, for example in
cases of necrotic tumours, (b) radiotherapy can lead to
tissue scarring and both CT and MRI have limitations in
differentiating scar tissue from viable tumour [18, 19], and
(c) accurately delineating tumour may be difficult, as (non-
enhanced) CT images lack contrast between normal soft
tissue structures and tumour extensions. In addition, (d)
inaccurate segmentation and misalignment also result in
PVC errors as is the case when one would use MRI data for
the same purpose.
Another possible PVC strategy of SUV data is to use a
lookup table with PVC factors as function of tumour volume,
where tumour volumes are either derived from a PET or a
(separate) CT study [20, 21]. It is, however, not easy to
estimate the true metabolic size on PET or CT images and
tumour shapes do not necessarily correspond with phantom
shapes (spheres) used to derive these factors. Another option
for generating PVC images is to include the scanner point
spread function (PSF) in the reconstruction process [22, 23].
The purposes of the present study were (a) to evaluate
the performance of several PET-based PVC methods for
oncological whole-body FDG PET studies and (b) to study
the effects of PVC on SUV accuracy, test-retest variability
and observed SUV responses.
Materials and methods
Reconstruction-based partial volume correction
The PVC ordered subsets expectation maximization (PVC-
OSEM) reconstruction algorithm similar to that of Brix et
al. [22] and Reader et al. [23] was implemented by taking
the PSF of the imaging system into account.
The PVC-OSEM algorithm, used in this study, works as
follows. The starting image, in this case a uniform image
with all voxels set to 1.0, is blurred with an isotropic 3-D
Gaussian shaped kernel, representing the 3-D PSF of the
system, resulting in a smoothed starting image. By forward
projecting this smoothed starting image, an estimated
sinogram is generated. Next, an updated sinogram is
calculated as the ratio between measured and estimated
sinograms. Subsequently, an updated image is generated by
backprojection of the updated sinogram. The estimated image
is multiplied by the updated image, resulting in a sharper
representation of the estimated image. This process is repeated
a certain number of times (iterations). The algorithm has been
described in detail elsewhere [24]. PVC-OSEM with matched
projectors (PVC-OSEM-M) additionally smooths the
updated image with a 3-D Gaussian shaped kernel that
represents the PSF of the system. This second additional
smoothing is not performed for PVC-OSEM using non-
matched projectors (PVC-OSEM-NM).
Image-based partial volume correction
Iterative deconvolution methods Deconvolution is an image
restoration process used to recover spatial resolution, restore
edges and improve contrast. Two PVC methods based on
iterative deconvolution were evaluated: Lucy-Richardson
(LR) [25] and Van Cittert deconvolution (VC) [17].
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The LR method is initialized using a copy of the original
PET image. This copy is smoothed with a Gaussian shaped
kernel that represents the PSF of the scanner. This smoothed
copy is subtracted from the original PET image and the differ-
ence is added to the copy of the original unsmoothed image.
Subsequently, the process starts again with the sharpened copy.
This loop is repeated until the smoothed copy is equal to the
original PET image, resulting in a sharper PET image. The VC
method is algorithmically similar to the LRmethod, except that
the ratio instead of the difference between original PET image
and smoothed copy is used to update the copy of the original
PET image. Note that LR and VC are very similar with the
exception that LR allows for negative pixel values.
Mask-based method In this method a tumour volume of
interest (VOI) is used as a mask and smoothed using a PSF that
matches the blurring effects of the PET scanner, including the
smoothing effects of reconstruction filters. In the present study
a isotropic 3-D Gaussian kernel of 6.5 mm FWHM provided a
good description of the shape of the PSF, as the image
resolution was primarily determined by (standard) Gaussian
post-smoothing of the iteratively reconstructed PET images.
The difference in average voxel value between smoothed and
original non-smoothed mask is a direct measure of the partial
volume effect (spill-out) for the tumour with its specific shape
and size. Spill-in of signal from surrounding activity is derived
by using an ‘inverted’mask, i.e. setting the voxel values within
the mask to zero and the surrounding pixels to the measured
average background value, and following the same procedure.
It should be noted that mask-based methods inherently assume
homogeneous tumour uptake.
Simulation studies
Simulations, representing 2-D mode acquisitions, were
performed using methodology and software as described
previously [4]. In short, an anatomically realistic mathe-
matical phantom was derived from a 2-D dynamic FDG
PET scan (ECAT EXACT HR+ scanner, CTI/Siemens,
Knoxville, TN, USA) of a patient. The scan data, acquired
from 15 to 60 min after administration of 370 MBq FDG,
were summed and the resulting sinogram was reconstructed
using OSEM [26] with 2 iterations and 16 subsets and post-
smoothed using a 6 mm FWHM Gaussian filter. It was
assumed that a nearly noise-free image was obtained by
first summing over 45 min and then applying additional
smoothing. Subsequently, voxel values were scaled, so that the
average soft tissue activity concentration equalled 5 kBq/ml,
which approximately corresponds to the average soft tissue
activity concentration observed in patient studies at 50–60 min
after injection of 370MBq FDG. Tumours of various sizes and
shapes were simulated by inserting volumes with increased
uptake in this mathematical phantom.
Next, noise-free sinograms were generated by forward
projection of the obtained image (i.e. entire 3-D volume).
These sinograms contained the number of true coincidences per
line of response. Random and scattered coincidences were
added to obtain sinogramswith prompt coincidences. Randoms
were assumed to be distributed uniformly over the sinogram.
Scattered coincidences were derived from forward projection
of the difference between a scatter-corrected and non-scatter-
corrected reconstructed image, using the same image data as
used for generating the true sinogram. Poisson noise was added
to the prompts, randoms and scatter sinograms. Finally, true
coincidences sinograms were generated by subtracting the
noisy random and scatter sinograms from the noisy prompt
sinograms. Number of counts corresponded to 2-D data
obtained for 5–7 min or about 1.5×107 noise equivalent
counts (NEC).
In total, 100 noisy images were obtained to derive the
variability of the ‘measured’ activity concentration both
with and without PVC and to determine to what extent
reproducibility of activity concentration measurements are
affected by PVC.
Phantom experiment
A phantom experiment was performed using the National
Electrical Manufacturers Association (NEMA) NU2 image
quality phantom containing 6 spheres with volumes of 26.5,
11.5, 5.6, 2.6, 1.2 and 0.5 ml (with diameters of 37, 28, 22, 17,
13 and 10 mm, respectively). The background compartment of
the phantom was filled with an FDG solution of 2 kBq/ml. All
spheres were filled with a solution of 20 kBq/ml, resulting in a
tumour to background ratio (TBR) of 10. The phantom was
scanned for 60 min on an ECAT EXACT HR+ scanner
(Siemens/CTI, Knoxville, TN, USA) in 2-D mode [27]. This
scanner has an axial field of view of 15 cm and produces 63
transaxial slices with a slice thickness of 2.5 mm. A 10-min
transmission scan was then acquired for attenuation and
scatter correction purposes. For this study, the average activity
concentrations in the spheres were compared with the true
activity concentration.
Clinical studies
Scans were performed in two separate groups of patients.
To study the impact of PVC on test-retest variability, a
group of ten patients (seven men and three women, mean
age: 50±5 years) with stage IIIB and IV non-small cell lung
cancer was scanned twice on 2 consecutive days before
receiving any treatment [28]. To investigate the effect of
PVC on PET response, a group of 15 female patients (mean
age: 52±8 years) with locally advanced breast cancer was
scanned before treatment and after one course of chemo-
therapy [29]. Both studies had been approved by the
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Medical Ethics Committee of the VU University Medical
Center and all patients gave written informed consent.
For both studies dynamic scans were performed using an
ECAT EXACT HR+ PET scanner in 2-D acquisition mode.
Patients were studied in the supine position with arms down
and with the dominant lesions in the centre of the field of view.
During the first scan, the distance between the suprasternal
notch and the upper side of the field of view (laser beam
alignment) was recorded and used for patient positioning
during the second scan.
All patients fasted for 6 h prior to scanning. Patients received
two venous catheters, one for injection of FDG contralateral to
the tumour, the other for venous blood sampling. Prior to
injection of FDG, a blood sample was collected for determi-
nation of plasma glucose level. Acquisition started with a 10- to
15-min transmission scan [28] to correct for attenuation and
scatter, followed by a bolus injection of 370 MBq of FDG in
5 ml saline through an injector (Medrad International,
Maastricht, The Netherlands) with 0.8 ml/s, after which the
line was flushed with 42 ml saline (2.0 ml/s). At the time of
the FDG injection, a dynamic emission scan (in 2-D mode)
was started with a total duration of 60 min and with variable
frame lengths (6×5, 6×10, 3×20, 5×30, 5×60, 8×150 and
6×300 s). All dynamic scan data were corrected for decay,
dead time, scatter, random coincidences and measured photon
attenuation.
In the present study, SUV with and without PVC were
calculated using the sum of the last three frames (i.e. 45–
60 min post-injection). In total, 30 and 18 lesions were
assessed in test-retest and response studies, respectively.
Reconstructions
All studies were reconstructed using both regular 2-D OSEM
and PVC-OSEM (either with matched or non-matched projec-
tors) with attenuation correction weighting. Regular OSEM
reconstructions were performedwith 2 iterations and 16 subsets,
and PVC-OSEM with 4 and 8 iterations for non-matched and
matched projectors, respectively, and 16 subsets. Reconstructed
image matrix size equalled 256×256 providing a voxel size of
2.57×2.57×2.43 mm. Image reconstructions included all
routine corrections required for quantification, such as scatter
correction, attenuation correction, normalization, and dead time
and decay corrections. Images without PVC were post-
smoothed using a Gaussian filter of 5 mm FWHM resulting in
an image resolution of about 6.5 mm FWHM. After recon-
struction, VC-, LR- or mask-based PVC methods were applied
to the regular (smoothed) 2-D OSEM reconstructed images.
Data analysis
Tumour VOI were defined using a 3-D region growing
algorithm, as described previously [4, 30]. This algorithm is
based on the 3-D search algorithm in the IDL software
package version 6.3 (Interactive Data Language, Research
Systems Inc., Boulder, CO, USA). In short, the program
first searched for the location of the maximum voxel value
within a (semi-automatically or manually) predefined
region. Next, using this maximum value and its location
as starting point, a 3-D VOI was defined automatically
using a 3-D region growing algorithm, including all voxels
above a specified threshold. This threshold was set at 41 or
50% of the sum of maximum and background values. The
latter (local) background value was derived automatically
using a 3-D shell of 1 voxel thickness at 1.5 cm from the
border of the initially estimated or (pre-)defined tumour
volume. This initial estimate is based on the 70% of
maximum pixel value 3-D isocontour [4, 29]. For volumes
larger than 4 ml, a threshold of 41% gives a reasonable
approximation of the true (tumour) volume [31]. For
smaller volumes (<4 ml), however, a decrease in TBR
increases the optimum threshold value due to the edge-
blurring effect of the background. A threshold value of
41%, adapted for local background, worked very well for
simulation and phantom data, but during analysis of clinical
data it occasionally failed to provide reliable and realistic
tumour VOI. Therefore, a higher threshold of 50%, adapted
for local background, was used for clinical data.
In addition to the PET-based VOI (PET VOI) mentioned
above, a second set of VOI was used for the simulation
studies. These VOI (exact VOI) were placed in exactly the
right position, and had the exact size and shape of the
simulated tumours, thereby excluding effects of PET-based
VOI inaccuracies and uncertainties.
For both simulation and phantom data the average activity
concentration within a VOI was measured. Subsequently,
recovery coefficients were derived by dividing these observed
activity concentrations by the ‘true’ simulated or experimen-
tally determined (well counter, calibrated against the dose
calibrator) activity concentrations.
For clinical studies, tumour VOI were defined on the
non-PVC-corrected images, smoothed with a Gaussian
kernel of 6.5 mm FWHM, before they were applied to the
various PVC images. SUV were normalized to body weight
and injected dose, and corrected for plasma glucose level.
In the case of clinical data ‘true’ SUV are not known and
therefore these data were only used to assess the impact of
PVC on test-retest variability or to investigate the effect of
PVC on (measured) response.
Results
LR and VC methods provided nearly identical results.
Therefore, in the remainder only results of the LR method
will be shown.
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Simulation studies
In the case of (standard) PET-based VOI, derived recovery
coefficients showed that all PVC methods investigated were
able to accurately correct for partial volume effects if
spheres were larger than 4 ml (Fig. 1a). When exact VOI
was used, recovery coefficients of PVC data were within
20%, even for the smallest VOI size (Fig. 1c).
Figure 1b, d show corresponding coefficients of variation
(COV) of the recovery coefficients for the various sphere
sizes. For both PET VOI and exact VOI the COV of the
recovery coefficient increases with decreasing sphere volume
and after applying PVC. In general, PVC-OSEM with
matched projectors showed the smallest increase (<30%) in
COV for both PETand exact VOI, when compared to all other
PVC methods (<46%).
Phantom experiment
The recovery coefficients of the six spheres positioned in
the NEMA NU2 image quality phantom are shown in
Fig. 2 for all PVC methods investigated. All these methods
were able to accurately recover true activity within 20% for
spheres equal or larger than 1 ml (Fig. 3).
Clinical studies
Figure 4 shows ratios between SUV with and without PVC
as function of tumour metabolic VOI, illustrating that PVC
increases SUV by 5–80% depending on metabolic volume
or VOI size.
In Fig. 5 percentage test-retest with PVC is shown as
function of test-retest without PVC. Test-retest variability
Fig. 1 Recovery coefficient (a, c) and its corresponding coefficient of variation (COV, b, d) as function of sphere size for PET-based VOI (a, b)
and exact VOI (c, d), respectively. Note that x-axis is plotted using a logarithmic scale
Fig. 2 Recovery coefficients of the six spheres positioned in the
NEMA NU2 image quality phantom. Note that x-axis is plotted using
a logarithmic scale
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slightly worsened from 9.8±6.5% before to 10.8±7.9%
after PVC. All methods showed an increase in test-retest
variability with decreasing metabolic tumour volume. The
p values of applying PVC compared to not applying PVC
ranged from 0.17 to 0.39 for the different methods.
Figure 6 illustrates the decrease in SUVafter the first cycle
of chemotherapy for the various PVC methods and provides
the corresponding p values of the changes compared to
baseline. PVC resulted in slightly smaller SUV responses,
i.e. from −31% without to −26 or −27% with PVC. Although
small, this effect was highly significant for all PVC methods
(p<0.05), except for the mask-based method (p>0.05).
Discussion
In this study the performance of various PVC methods
(either image, mask or reconstruction based) was evaluated
for whole-body oncological FDG PET studies, focussing on
the impact of PVC on accuracy of SUV quantification, test-
retest variability and magnitude of SUV response.
Simulation studies and phantom experiment
In clinical data the ground truth is not known and consequently
these data cannot be used directly to assess the accuracy of
PVCmethods. Therefore, simulation and phantom experiments
were performed to assess the performance of PVC. Clinical
data are mainly used to show the impact of using PVC on test-
retest variability and FDG response assessment. In the
simulation studies, all PVC methods accurately corrected
SUV for partial volume effects when tumours (spheres) were
larger than 4 ml (20 mm diameter). Interestingly, when known
information about location and size was used (exact VOI), the
accuracy of all PVCmethods improved to within 20%, even for
the smallest tumour size investigated. Apparently, accurate
tumour VOI definition is needed for PVC of small structures. It
could be hypothesized that this information could be obtained
using CT. In practice, however, this appears not to be the case,
as both observer variability in tumour definition [32–35] and
target motion (e.g. due to breathing) will likely result in some
mismatch between the ‘real’ tumour volume and that defined
on CT.
The simulation studies also showed an increase in COVof
the recovery coefficient with decreasing tumour volume
following PVC. Of all the PVC methods investigated, PVC-
OSEM with matched projectors showed the smallest increase
in COV.
Results obtained using the NEMA NU2 image quality
phantom were consistent with those seen during simulations.
All PVC methods were able to accurately recover true SUV
within 20% for spheres equal to or larger than 1 ml.
Clinical studies
In clinical data the true activity concentration and its distribu-
tion within a tumour are not known, making it impossible to
Fig. 5 Percentage test-retest with PVC plotted against test-retest without
PVC
Fig. 4 Ratios between SUV with and without PVC plotted against
metabolic tumour volume
Fig. 3 Visual comparison of PVC-corrected images. From left to right: no PVC, imaged-based PVC (LR) and reconstruction-based PVC (PVC-OSEM-M)
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assess the accuracy of any PVC method. Nevertheless, a
number of important performance characteristics can be
derived from clinical data, such as its impact on test-retest
variability, on metabolic tumour volume dependence and on
measured SUV response.
Test-retest variability of FDG SUV measurements
acquired for the same patient on 2 consecutive days
increased from 9.8% without to 10.8% with PVC, but this
effect was not significant (p>0.17). This may suggest that
use of PVC does not worsen SUV precision and that it
would therefore not affect the sensitivity of detecting
changes in SUV for longitudinal studies provided that
these were not caused by changes in size alone. However,
the main reason for applying PVC is to rule out the effects
of volumetric changes on SUV responses. As PVC did not
change test-retest variability, it suggests that PVC provides
more accurate assessments of treatment response without
affecting its precision.
When assessing tumour response the accuracy of measured
changes needs to be balanced against its reproducibility. In
addition, PVC might be required to avoid incorrect SUV
responses due to changes in tumour volume rather than
uptake. All PVCmethods investigated were able to reduce the
dependency of SUVon tumour volume (Fig. 4). However, a
small volumetric SUV dependency was still present for small
tumours, which was also observed in the simulation studies
and the phantom experiment. Eventually, application of PVC
resulted in a significant effect on the observed SUV
responses for most PVC methods (Fig. 6). However, use of
the mask-based PVC method did not show a different SUV
response as compared with the non-PVC SUV data. A
possible explanation is that the mask-based method uses a
VOI directly to derive correction factors (while this is not the
case for the image- or reconstruction-based methods). In
patient data reproducible VOI are more difficult to generate
and may thus have a larger impact on the mask-based PVC
method performance. As test-retest variability was not
significantly affected by using image- and reconstruction-
based PVC, it may be concluded that both image- and
reconstruction-based PVC can be used for more accurate, yet
equally precise treatment response assessments.
Limitations/ future research
In the present implementation of all PVC methods, the PSF
of the scanner was approximated by a single 3-D isotropic
Gaussian function. For most scanners resolution is not
spatially invariant, but decreases with increasing distance
from the centre [27]. These spatial resolutions are measured
using point sources in air and data are reconstructed using
filtered backprojection using voxel sizes of about 1 mm (as
recommended by NEMA NU 2 specifications). In onco-
logical whole-body PET studies, however, iterative recon-
struction algorithms are used with voxel sizes of 2.5–5 mm.
In addition, resulting images are often post-smoothed using
Gaussian filters of 5–10 mm (5 mm in the present study).
Consequently, actual image resolution is primarily determined
by image reconstruction settings (e.g. number of iterations and
subsets used within OSEM) and post-reconstruction filtering.
As these degrading effects are spatially invariant, the
assumption that, in clinical studies, the PSF may be
approximated by a single Gaussian function appears reason-
able. This is supported by the good results obtained with the
phantom experiment, where spheres were located at different
positions within the field of view of the scanner. Moreover, the
present results are consistent with those of Geworski et al. [6]
who, when studying the feasibility of recovery correction in
PET, showed that criteria for linearity and stationarity of a
similar PET scanner were sufficiently met to allow for
recovery correction. Nevertheless, future research should
investigate whether implementation of spatial variation in
PSF would improve results.
The performance of image-based PVC methods using
iterative deconvolution can be further enhanced when a
priori information is incorporated during the process. For
example, use of Gibbs or median root priors may be helpful
in reducing or avoiding image noise amplification during
iterative deconvolution. The latter requires further inves-
tigations and optimization of prior settings and will be part
of future research. With the present implementations of
iterative deconvolution-based PVC methods, however, we
have already shown that PVC can improve SUV accuracy
and responses.
The present simulation studies suggest that more accurate
PVC results can be obtained using exact VOI definition, or
e.g. VOI derived from CT data. In clinical practice, however,
CT-based VOI may suffer from observer variability [32–35].
Indeed, it has been reported that observer variation and
misregistration range from 2 to 15 mm for the different
image fusion methods [36, 37]. Accurate registration of PET
Fig. 6 Average decrease in SUV after the first cycle of chemotherapy,
shown for various PVC methods. The p values of the PVC methods
compared to no PVC are shown above the bars
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with CT is required, as misregistration can contribute to
errors in PVC.
In both simulation and phantom studies only the effects
of applying PVC on homogeneous tumours were investi-
gated. In practice, however, tumours can be very heteroge-
neous. Tumour heterogeneity may lead to a decrease in
contrast, which in turn may make tumour VOI definitions
more problematic. From the clinical data we already
observed that a higher threshold (50%) was needed to
generate VOI reliably, while a lower threshold (41%) could
be used for (simple) phantoms. Especially for image- and
reconstruction-based PVC methods, the impact of using a
somewhat higher threshold is likely minimal as both these
PVC methods use only the PSF kernel for applying PVC.
The use of the slightly higher threshold resulted in <5%
higher SUV data for most tumours [29, 33], which is very
small compared to the amplitude of PVC for most tumours,
and it will therefore likely not affect the main conclusions
of this paper. Of course, the best situation would be to have
automated VOI methods that can take uptake heterogeneity
into account and these methods will likely further increase
the accuracy of SUV (with and without PVC). At present,
novel algorithms are being developed to generate accurate
VOI in cases of heterogeneous tracer uptake [38] and those
methods will need to be explored further.
An issue not addressed in this study is the effect of
breathing on PET-based VOI definition and SUV quantifi-
cation. In cases of e.g. lung tumours, breathing will cause
additional blurring of the PET images. This blurring will
not only result in decreased SUV but also in incorrect PET-
based VOI definitions [33, 39]. As the smoothing effect due
to breathing is not isotropic, it cannot easily be corrected
for using PVC strategies such as those in the present study.
A potential solution for this problem is to perform
respiratory-gated PET acquisitions. A PVC method may
then be applied to each of the acquisition gates separately.
The accuracy of this approach, however, needs to be
established in future studies.
Finally, all image data in this study were acquired in 2-D
mode. At present all modern PET or PET/CT systems are
3-D mode systems, having higher sensitivity and better
count rate performances and thus providing data with better
image quality and/or less noise. Collecting data with
improved image quality or less noise will further enhance
the applicability of the presented PVC methods. Especially
image-based methods, which can be applied after recon-
struction and thus off-line, cause a larger increase of image
noise (Fig. 1) than reconstruction-based methods and may
therefore be less suitable for scans acquired in 2-D mode.
Reconstruction-based PVC should then be preferred, but it
is not routinely available on all machines. Yet, already
promising results were obtained for both reconstruction- as
well as image-based PVC methods and it is expected that
these methods will perform at least equally well, if not
better (due to smaller problems with image noise), in cases
of 3-D mode acquisitions.
Conclusion
This study demonstrates that various PVC methods improve
accuracy of tumour SUV estimation without decreasing test-
retest variability. In addition, except for mask-based PVC,
there is a significant but small effect on observed tumour
responses. PVC-OSEM with matched projectors seems to be
the optimal PVC method, as it provides best accuracy and
precision. A disadvantage is the need for dedicated recon-
struction software, which is not yet fully available for all PET/
CT systems. The results in this paper demonstrate that both
image- and reconstruction-based PVC can be applied to
improve SUVaccuracy without worsening test-retest variabil-
ity. Consequently, PVC can be used for more accurate, yet
equally precise treatment response assessments.
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